S
Shandong Keyuan Pharmaceutical Co Ltd
SZSE:301281
Shandong Keyuan Pharmaceutical Co Ltd
SZSE:301281
Price:
33.63
CNY
2.41%
Market Cap:
¥2.4B
Income Statement
Earnings Waterfall
Shandong Keyuan Pharmaceutical Co Ltd
Shandong Keyuan Pharmaceutical Co Ltd
Income Statement
Shandong Keyuan Pharmaceutical Co Ltd
Shandong Keyuan Pharmaceutical Co Ltd
Currency: CNY
| Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
349
N/A
|
448
+28%
|
369
-17%
|
460
+25%
|
438
-5%
|
464
+6%
|
429
-8%
|
454
+6%
|
436
-4%
|
|
| Gross Profit | ||||||||||
| Cost of Revenue |
(185)
|
(239)
|
(219)
|
(277)
|
(273)
|
(266)
|
(233)
|
(226)
|
(207)
|
|
| Gross Profit |
164
N/A
|
208
+27%
|
150
-28%
|
184
+22%
|
165
-10%
|
198
+20%
|
195
-1%
|
228
+17%
|
228
+0%
|
|
| Operating Income | ||||||||||
| Operating Expenses |
(98)
|
(146)
|
(117)
|
(138)
|
(130)
|
(145)
|
(146)
|
(175)
|
(189)
|
|
| Selling, General & Administrative |
(65)
|
(100)
|
(81)
|
(104)
|
(103)
|
(120)
|
(115)
|
(133)
|
(137)
|
|
| Research & Development |
(34)
|
(42)
|
(37)
|
(44)
|
(36)
|
(32)
|
(37)
|
(39)
|
(49)
|
|
| Depreciation & Amortization |
0
|
(8)
|
0
|
0
|
0
|
(8)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
1
|
4
|
2
|
10
|
9
|
15
|
6
|
(3)
|
(2)
|
|
| Operating Income |
66
N/A
|
62
-5%
|
34
-46%
|
45
+35%
|
34
-24%
|
53
+53%
|
49
-7%
|
53
+7%
|
40
-25%
|
|
| Pre-Tax Income | ||||||||||
| Interest Income Expense |
8
|
18
|
16
|
22
|
19
|
16
|
15
|
12
|
11
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
(0)
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
|
| Total Other Income |
(0)
|
(0)
|
(1)
|
(2)
|
(3)
|
(2)
|
2
|
4
|
4
|
|
| Pre-Tax Income |
73
N/A
|
80
+9%
|
48
-39%
|
66
+36%
|
51
-22%
|
66
+28%
|
66
+1%
|
69
+4%
|
55
-20%
|
|
| Net Income | ||||||||||
| Tax Provision |
(4)
|
(3)
|
(1)
|
(4)
|
(1)
|
(5)
|
(4)
|
(2)
|
(3)
|
|
| Income from Continuing Operations |
70
|
77
|
47
|
62
|
50
|
60
|
62
|
67
|
52
|
|
| Income to Minority Interest |
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
70
N/A
|
77
+10%
|
47
-39%
|
62
+31%
|
50
-19%
|
60
+20%
|
62
+3%
|
67
+8%
|
52
-22%
|
|
| EPS (Diluted) |
0.65
N/A
|
0.71
+9%
|
0.44
-38%
|
0.57
+30%
|
0.46
-19%
|
0.56
+22%
|
0.57
+2%
|
0.62
+9%
|
0.48
-23%
|
|
Switch to:
Switch to:
See Also
Discover More
